{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T06:42:29Z","timestamp":1794724949327,"version":"4.9.1"},"reference-count":17,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,13]]},"DOI":"10.1182\/bloodadvances.2024015648","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T21:01:19Z","timestamp":1739394079000},"page":"2155-2158","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma"],"prefix":"10.1182","volume":"9","author":[{"given":"Bhavesh","family":"Mohan Lal","sequence":"first","affiliation":[{"name":"1Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0531-918X","authenticated-orcid":false,"given":"Marah","family":"Alzubi","sequence":"additional","affiliation":[{"name":"2Department of Internal Medicine, University of Jordan, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawad","family":"Alrawabdeh","sequence":"additional","affiliation":[{"name":"2Department of Internal Medicine, University of Jordan, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"John D.","family":"Shaughnessy","sequence":"additional","affiliation":[{"name":"3Department of Hematology and Oncology, Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5417-2973","authenticated-orcid":false,"given":"Fenghuang","family":"Zhan","sequence":"additional","affiliation":[{"name":"3Department of Hematology and Oncology, Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9824-6612","authenticated-orcid":false,"given":"Eric R.","family":"Siegel","sequence":"additional","affiliation":[{"name":"4Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2699-1741","authenticated-orcid":false,"given":"Carolina","family":"Schinke","sequence":"additional","affiliation":[{"name":"3Department of Hematology and Oncology, Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmilan","family":"Thanendrarajan","sequence":"additional","affiliation":[{"name":"3Department of Hematology and Oncology, Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Zangari","sequence":"additional","affiliation":[{"name":"3Department of Hematology and Oncology, Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frits","family":"van Rhee","sequence":"additional","affiliation":[{"name":"3Department of Hematology and Oncology, Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Al Hadidi","sequence":"additional","affiliation":[{"name":"3Department of Hematology and Oncology, Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"issue":"4","key":"2025051213220994800_bib1","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"issue":"21","key":"2025051213220994800_bib2","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1158\/1078-0432.CCR-22-0618","article-title":"FDA approval summary: belantamab mafodotin for patients with relapsed or refractory multiple myeloma","volume":"28","author":"Baines","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025051213220994800_bib3","unstructured":"GSK\n          . GSK provides an update on Blenrep (belantamab mafodotin-blmf) US marketing authorisation. Accessed 15 August 2024. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-provides-update-on-blenrep-us-marketing-authorisation\/."},{"issue":"2","key":"2025051213220994800_bib4","doi-asserted-by":"crossref","DOI":"10.58877\/japaj.v1i2.56","article-title":"Real-world use of belantamab mafodotin in relapsed\/refractory multiple myeloma: a systematic review","volume":"1","author":"Nanah","year":"2023","journal-title":"JAP Acad J"},{"issue":"5","key":"2025051213220994800_bib5","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2403407","article-title":"Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma","volume":"391","author":"Dimopoulos","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"2025051213220994800_bib6","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa2405090","article-title":"Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma","volume":"391","author":"Hungria","year":"2024","journal-title":"N Engl J Med"},{"key":"2025051213220994800_bib7","unstructured":"U.S. Food and Drug Administration\n          . FDA approves idecabtagene vicleucel for multiple myeloma. Accessed 21 August 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-idecabtagene-vicleucel-multiple-myeloma."},{"issue":"11","key":"2025051213220994800_bib8","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"2025051213220994800_bib9","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"2025051213220994800_bib10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"issue":"4","key":"2025051213220994800_bib11","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1182\/blood.2023023557","article-title":"Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma","volume":"144","author":"Firestone","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2025051213220994800_bib12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-023-00886-8","article-title":"Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy","volume":"13","author":"Ferreri","year":"2023","journal-title":"Blood Cancer J"},{"issue":"S2","key":"2025051213220994800_bib13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/01.HS9.0000936292.14792.3e","article-title":"No evidence of B-cell maturation antigen (BCMA) expression loss or systemic immune impairment after treatment with the BCMA-targeted antibody-drug conjugate belantamab mafodotin in patients with relapsed\/refractory multiple myeloma","volume":"7","author":"Lowther","year":"2023","journal-title":"HemaSphere"},{"issue":"3","key":"2025051213220994800_bib14","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1182\/blood.2022018157","article-title":"Sequencing anti-BCMA therapies in myeloma","volume":"141","author":"Harousseau","year":"2023","journal-title":"Blood"},{"issue":"5","key":"2025051213220994800_bib15","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1056\/NEJMe2406799","article-title":"A belantamab mafodotin revival in multiple myeloma therapy","volume":"391","author":"Trudel","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"2025051213220994800_bib16","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"2025051213220994800_bib17","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/9\/2155\/2371717\/blooda_adv-2024-015648-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/9\/2155\/2371717\/blooda_adv-2024-015648-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T17:22:18Z","timestamp":1747070538000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/9\/2155\/535577\/Prior-exposure-to-belantamab-mafodotin-influences"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":17,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,5,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015648","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]}}}